← Browse by Condition
Medical Condition
minimal residual disease
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2
NCT07136077 Phase 2
Recruiting
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Enrollment
20 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06287814
Recruiting
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
Enrollment
70 pts
Location
France
Sponsor
University Hospital, Montpelli...
NCT06463717
Recruiting
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
Enrollment
210 pts
Location
China
Sponsor
First Affiliated Hospital of Z...